TB-500 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-17. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
== Platyhelminthes == Clonorchis sinensis, liver fluke (human pathogen) (draft 2011) Echinococcus granulosus, tapeworm (dog pathogen) (2013, 2013) Echinococcus multilocularis, tapeworm (2013) Hymenolepis microstoma, tapeworm (2013) Schistosoma haematobium, schistosome (human pathogen) (2012 2019) Schistosoma japonicum, schistosome (human pathogen) (2009) Schistosoma mansoni, schistosome (human pathogen) (2009, 2012) Schmidtea mediterranea, planarian (model organism) (2006) Taenia solium, tapeworm (2013)
==== Other musculoskeletal disorders ==== There is limited, low-quality evidence of a slight benefit of noxious-level electrotherapy in the treatment of epicondylitis. A 2012 review found that "Small, single studies showed that some electrotherapy modalities may be beneficial" in rehabilitating ankle bone fractures, but the 2024 update of this review does not address electrotherapy. However, a 2008 review found it to be ineffective in healing long-bone fractures. A 2012 review found that evidence that electrotherapy contributes to recovery from knee conditions is of "limited quality".
=== Breeding === Like many other gouramis, the male croaking gourami is a bubblenest builder, creating a small nest from air bubbles and mucus under a leaf. The water level should be reduced to 20 cm (7.9 in) during spawning, circulation kept minimal, and the temperature should be approximately 28 °C (82 °F). Spawning occurs under the nest, with the female responding to the male's dance by rolling over, followed by the typical gourami embrace. About 5 to 10 eggs are released in a quick burst. The male will grab the eggs and spit them into the nest, often adding a few more bubbles for good measure. This act may be repeated a dozen times or more until about 100 eggs are laid (some large females may lay more than 200). After spawning, the female should be moved to a different tank (to prevent her from eating the eggs). The male will keep the bubblenest maintained and tend to the eggs and fry, but when the fry are 2 to 3 days old, the male should also be removed (for the same reason). When first hatched, the fry should be fed infusoria, and later, baby brine shrimp and fine ground flakes. Freeze-dried tablets may also be fed to older fry.
28 September The 15-year-old girl killed in Croydon, South London the previous day is named locally as Elianne Andam. Police are given an extra 24 hours to question the 17-year-old suspect. The landmark Sycamore Gap Tree, beside Hadrian's Wall in Northumberland, is illegally felled. A 16-year-old boy is subsequently arrested on suspicion of criminal damage. 29 September A school bus carrying 58 people overturns between junction 4 and 5 of the M53 motorway, killing a 15-year-old girl and the driver. A major incident is declared by North West Ambulance Service and Liverpool's Alder Hey Children's Hospital. Dozens of others are treated for injuries, and several are hospitalised. A 17-year-old boy appears in court charged with the murder of Elianne Andam, and is remanded in youth detention to appear before the Old Bailey on 3 October. A second person – a man in his 60s – is arrested in correction with the cutting-down of the world-famous Sycamore Gap Tree. The 16-year-old boy arrested over the incident the previous day is released on bail. In an interview with The Sun, Prime Minister Rishi Sunak reinforces his pro-motorist stance, saying he wants to stop "hare-brained" road calming and safety schemes – including 20 mph zones and low-traffic neighbourhoods – putting an end to what he refers to as a "war on motorists".
==== Separation methods ==== For the analysis of complex biological samples, a reduction of sample complexity is required. This may be performed off-line by one-dimensional or two-dimensional separation. More recently, on-line methods have been developed where individual peptides (in bottom-up proteomics approaches) are separated using reversed-phase chromatography and then, directly ionized using ESI; the direct coupling of separation and analysis explains the term "on-line" analysis.
Sources: en.wikipedia.org
Unlike the A and P sites, the E site contains more proteins. Because proteins are not essential for the functioning of the A and P sites, the E site molecular composition shows that it is perhaps evolved later. In primitive ribosomes, it is likely that tRNAs exited from the P site. Additionally, it has been shown that E-site tRNA bind with both the 16S and 23S rRNA subunits.
== Sizes == While small-scale columns range from inner diameters of 0.5 cm and withstand pressures of up to 130 MPa, industrial large scale columns reach diameters of up to 2 m and operate at considerable lower pressures (below 1 MPa). While it is favorable to view the packed bed of a column large scale columns are manufactured from steel due to its superior resilience. Chromatography columns can be used as stand-alone devices or in combination with manual or automated chromatography systems. Medium to large columns are almost exclusively operated together with automated systems to decrease the risk of process failure and loss of product.
von Hagens, Gunther (March 1986). Heidelberg plastination folder: collection of technical leaflets of plastination. Heidelberg: Biodur Products. OCLC 256499636. First published as von Hagens, Gunther (1985). Heidelberger Plastinationshefter Sammlung von Merkblättern zur Plastination (in German). Heidelberg: University of Heidelberg. OCLC 174501422. da Fonseca, Liselotte Hermes; Thomas Kliche (2007). "Verführerische Leichen – verbotener Verfall. "Körperwelten" als gesellschaftliches Schlüsselereignis. Perspektiven Politischer Psychologie". Deutsches Ärzteblatt (in German). 104 (38). von Hagens, Gunther; Klaus Tiedemann; Wilhelm Kriz (March 1987). "The current potential of plastination". Anatomy and Embryology. 175 (4): 411–21. doi:10.1007/BF00309677. PMID 3555158. S2CID 21077765. Whalley, Angelina (2005). Pushing the Limits: Encounters with Body Worlds Creator Gunther von Hagens. Heidelberg: Arts & Sciences. ISBN 978-3-937256-07-8. OCLC 61119531. von Hagens, Gunther (2006). Body Worlds: The Anatomical Exhibition of Real Human Bodies. Heidelberg: Institute für Plastination. ISBN 978-3-937256-04-7. OCLC 69257041. Ottone NE et al. (2015). New contributions to the development of a plastination technique at room temperature with silicone. Anatomical Science International 2015; 90(2):126–35. doi:10.1007/s12565-014-0258-6 Ottone NE et al. (2018). E12 sheet plastination: Techniques and applications. Clinical Anatomy, 31(5):742–756. doi:10.1002/ca.23008 Ottone NE et al. (2020). Extraction of DNA from plastinated tissues. Forensic Science International, 309:110199.
=== Infertility === It can be difficult to become pregnant with PMOS due to irregular ovulation. The first management step is to improve the general health of the mother, such as through lifestyle interventions. GLP-1 agonist for weight loss can be used, but should be stopped at least 2 months before conception. As of 2025, there is not enough data to know if they are safe in pregnancy. Pregnancy in PMOS is more risky than normal, and treatment is focused on getting a single pregnancy, rather than, for instance, twins (multiple pregnancy). With treatment, the eventual family size of women with PMOS does not seem different to those without. The first-line medical treatment for infertility in women with PMOS is letrozole (Femara) to induce ovulation. This is, in general, more effective than clomiphene citrate to improve both pregnancy rates and live births. Other medications that can be used to treat infertility, listed from most to least effective, are metformin + clomiphene citrate, clomiphene citrate alone, and metformin alone. Women may be more likely to experience gastrointestinal side effects with metformin. Gonadotrophin therapy may be effective too, but requires monitoring and increases the risks of multiple pregnancies. When medication and lifestyle interventions are ineffective, infertility can be treated with a laparoscopic procedure called "ovarian drilling", which involves puncture of 4–10 small follicles with electrocautery, laser, or biopsy needles.
Sources: en.wikipedia.org
=== Adobe ColdFusion (2018 Release) === Adobe ColdFusion (2018 release), known generically as ColdFusion 2018, was released on July 12, 2018. ColdFusion 2018 was codenamed Aether during prerelease. As of March 2023, Adobe had released 16 updates for ColdFusion 2018. New or improved features available in all editions (Standard, Enterprise, and Developer) include:
== Role in the immune system == The proteasome plays a straightforward but critical role in the function of the adaptive immune system. Peptide antigens are displayed by the major histocompatibility complex class I (MHC) proteins on the surface of antigen-presenting cells. These peptides are products of proteasomal degradation of proteins originated by the invading pathogen. Although constitutively expressed proteasomes can participate in this process, a specialized complex composed of proteins, whose expression is induced by interferon gamma, are the primary producers of peptides which are optimal in size and composition for MHC binding. These proteins whose expression increases during the immune response include the 11S regulatory particle, whose main known biological role is regulating the production of MHC ligands, and specialized β subunits called β1i, β2i, and β5i with altered substrate specificity. The complex formed with the specialized β subunits is known as the immunoproteasome. Another β5i variant subunit, β5t, is expressed in the thymus, leading to a thymus-specific "thymoproteasome" whose function is as yet unclear. The strength of MHC class I ligand binding is dependent on the composition of the ligand C-terminus, as peptides bind by hydrogen bonding and by close contacts with a region called the "B pocket" on the MHC surface. Many MHC class I alleles prefer hydrophobic C-terminal residues, and the immunoproteasome complex is more likely to generate hydrophobic C-termini.
miscibility The tendency or capability of two or more substances to blend uniformly when combined (most commonly liquids, though the concept is also applicable to solids and gases), i.e. to dissolve in each other, forming a homogeneous mixture that exists in a single phase, without separation of phases, regardless of the proportions of each substance. Substances that do not mix uniformly in all proportions are said to be immiscible.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.